which glp-1 agonists have cardiovascular benefit Receptor in Heart Failure Management GLP-1 Agonists in Cardiovascular Diseases:

It targets GLP-1, GIP, and glucagon receptors simultaneously, adding a third mechanism that directly increases energy expenditure and fat oxidation through the liver

doi: 10.1111/dom.12076

10.1007/s40279-015-0385-9 [DOI] [PMC free article] [PubMed] [Google Scholar] 47

Exenatide (Byetta and Bydureon, AstraZeneca), is a synthetic 39-amino acid peptide (first discovered as exendin-4 in the saliva of the gila monster, Heloderma suspectum) (Figure 8) [879]

Due to a lack of coding in the dataset, we were unable to report more nuanced and specific metrics such as duration of diabetes, total daily dose of insulin, percentage time in range and reason for starting adjunctive therapy, all of which are clinically relevant